{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:26:20Z","timestamp":1783164380924,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070149"],"award-info":[{"award-number":["82070149"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00262-023-03454-y","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:03:20Z","timestamp":1683799400000},"page":"2769-2782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent\u2009+\u2009CAG regimen in patients with relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"72","author":[{"given":"Xiao-Ning","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Feng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Fen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"3454_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A (2020) Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol 21:66. https:\/\/doi.org\/10.1007\/s11864-020-00765-5","journal-title":"Curr Treat Options Oncol"},{"key":"3454_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1468-0734.2002.00058.x","volume":"6","author":"AK Burnett","year":"2002","unstructured":"Burnett AK (2002) Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol 6:26\u201345. https:\/\/doi.org\/10.1046\/j.1468-0734.2002.00058.x. (Discussion 86\u201327)","journal-title":"Rev Clin Exp Hematol"},{"key":"3454_CR3","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/jco.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969\u20131978. https:\/\/doi.org\/10.1200\/jco.2005.06.027","journal-title":"J Clin Oncol"},{"key":"3454_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/jco.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487\u2013494. https:\/\/doi.org\/10.1200\/jco.2010.30.1820","journal-title":"J Clin Oncol"},{"issue":"7","key":"3454_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","volume":"121","author":"SJ Forman","year":"2013","unstructured":"Forman SJ, Rowe JM (2013) The myth of the second remission of acute leukemia in the adult. Blood 121(7):1077\u20131082. https:\/\/doi.org\/10.1182\/blood-2012-08-234492","journal-title":"Blood"},{"issue":"8","key":"3454_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O\u2019Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS (2018) Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol 93(8):1074\u20131081. https:\/\/doi.org\/10.1002\/ajh.25162","journal-title":"Am J Hematol"},{"key":"3454_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","volume":"136","author":"S DeWolf","year":"2020","unstructured":"DeWolf S, Tallman MS (2020) How I treat relapsed or refractory AML. Blood 136:1023\u20131032. https:\/\/doi.org\/10.1182\/blood.2019001982","journal-title":"Blood"},{"key":"3454_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood.2021010721","volume":"139","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P et al (2022) Phase 1\/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood 139:1135\u20131146. https:\/\/doi.org\/10.1182\/blood.2021010721","journal-title":"Blood"},{"key":"3454_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE et al (2019) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125:1470\u20131481. https:\/\/doi.org\/10.1002\/cncr.31896","journal-title":"Cancer"},{"key":"3454_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C et al (2020) Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol 13:28. https:\/\/doi.org\/10.1186\/s13045-020-00853-x","journal-title":"J Hematol Oncol"},{"key":"3454_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA et al (2022) A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv 6:2219\u20132229. https:\/\/doi.org\/10.1182\/bloodadvances.2021006138","journal-title":"Blood Adv"},{"key":"3454_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cei.13081","volume":"191","author":"RAM Wilson","year":"2018","unstructured":"Wilson RAM, Evans TRJ, Fraser AR, Nibbs RJB (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clin Exp Immunol 191:133\u2013148. https:\/\/doi.org\/10.1111\/cei.13081","journal-title":"Clin Exp Immunol"},{"key":"3454_CR13","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M et al (2010) Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116:2484\u20132493. https:\/\/doi.org\/10.1182\/blood-2010-03-275446","journal-title":"Blood"},{"key":"3454_CR14","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.Ccr-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M et al (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044\u20133051. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4079","journal-title":"Clin Cancer Res"},{"key":"3454_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/jep.S254334","volume":"12","author":"F Pourrajab","year":"2020","unstructured":"Pourrajab F, Zare-Khormizi MR, Hekmatimoghaddam S, Hashemi AS (2020) Molecular targeting and rational chemotherapy in acute myeloid leukemia. J Exp Pharmacol 12:107\u2013128. https:\/\/doi.org\/10.2147\/jep.S254334","journal-title":"J Exp Pharmacol"},{"key":"3454_CR16","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1158\/0008-5472.Can-11-0950","volume":"71","author":"J Fucikova","year":"2011","unstructured":"Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al (2011) Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71:4821\u20134833. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-0950","journal-title":"Cancer Res"},{"key":"3454_CR17","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.18632\/oncotarget.7235","volume":"7","author":"M Black","year":"2016","unstructured":"Black M, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M et al (2016) Activation of the PD-1\/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 7:10557\u201310567. https:\/\/doi.org\/10.18632\/oncotarget.7235","journal-title":"Oncotarget"},{"key":"3454_CR18","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell M, Peleteiro Ra\u00edndo A, Climent Medina J, G\u00f3mez Centuri\u00f3n I, Mosquera Orgueira A (2022) Immune checkpoint inhibitors in acute myeloid leukemia: a meta-analysis. Front Oncol 12:882531. https:\/\/doi.org\/10.3389\/fonc.2022.882531","journal-title":"Front Oncol"},{"key":"3454_CR19","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28:1280\u20131288. https:\/\/doi.org\/10.1038\/leu.2013.355","journal-title":"Leukemia"},{"key":"3454_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020236","author":"K Giannopoulos","year":"2019","unstructured":"Giannopoulos K (2019) Targeting immune signaling checkpoints in acute myeloid leukemia. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8020236","journal-title":"J Clin Med"},{"key":"3454_CR21","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-2762","volume":"13","author":"T Qin","year":"2007","unstructured":"Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP (2007) Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13:4225\u20134232. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2762","journal-title":"Clin Cancer Res"},{"key":"3454_CR22","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.18632\/aging.102973","volume":"12","author":"M Hong","year":"2020","unstructured":"Hong M, Zhu H, Sun Q, Zhu Y, Miao Y, Yang H, Qiu HR, Li JY, Qian SX (2020) Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML. Aging (Albany NY) 12:5792\u20135811. https:\/\/doi.org\/10.18632\/aging.102973","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"3454_CR23","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s00277-019-03674-2","volume":"98","author":"X Zhang","year":"2019","unstructured":"Zhang X, Guo X (2019) Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia. Ann Hematol 98(9):2223\u20132225. https:\/\/doi.org\/10.1007\/s00277-019-03674-2","journal-title":"Ann Hematol"},{"key":"3454_CR24","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/jco.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649. https:\/\/doi.org\/10.1200\/jco.2003.04.036","journal-title":"J Clin Oncol"},{"issue":"1","key":"3454_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW (1984) A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 3(1):35\u201344. https:\/\/doi.org\/10.1002\/sim.4780030106","journal-title":"Stat Med"},{"key":"3454_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","volume":"93","author":"B Tawfik","year":"2014","unstructured":"Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S et al (2014) Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol 93:47\u201355. https:\/\/doi.org\/10.1007\/s00277-013-1940-9","journal-title":"Ann Hematol"},{"key":"3454_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA et al (2018) Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv 2:923\u2013932. https:\/\/doi.org\/10.1182\/bloodadvances.2018016121","journal-title":"Blood Adv"},{"key":"3454_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.Cd-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE et al (2019) Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label. Phase II Study Cancer Discov 9:370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0774","journal-title":"Phase II Study Cancer Discov"},{"key":"3454_CR29","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"3454_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:57\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"3454_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"key":"3454_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/life11121318","author":"D Machiraju","year":"2021","unstructured":"Machiraju D, Sch\u00e4fer S, Hassel JC (2021) Potential reasons for unresponsiveness to anti-PD1 immunotherapy in young patients with advanced melanoma. Life (Basel). https:\/\/doi.org\/10.3390\/life11121318","journal-title":"Life (Basel)"},{"key":"3454_CR33","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.Ccr-18-1116","volume":"24","author":"CH Kugel 3rd","year":"2018","unstructured":"Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X et al (2018) Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res 24:5347\u20135356. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1116","journal-title":"Clin Cancer Res"},{"key":"3454_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.022","volume":"119","author":"L Bastholt","year":"2019","unstructured":"Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM (2019) Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Eur J Cancer 119:122\u2013131. https:\/\/doi.org\/10.1016\/j.ejca.2019.06.022","journal-title":"Eur J Cancer"},{"key":"3454_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf \u00c5 et al (2015) Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 90:208\u2013214. https:\/\/doi.org\/10.1002\/ajh.23908","journal-title":"Am J Hematol"},{"key":"3454_CR36","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1002\/cncr.24367","volume":"115","author":"G Borthakur","year":"2009","unstructured":"Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O\u2019Brien S et al (2009) Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115:3217\u20133221. https:\/\/doi.org\/10.1002\/cncr.24367","journal-title":"Cancer"},{"key":"3454_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2403187","volume":"18","author":"C Schoch","year":"2004","unstructured":"Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T (2004) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18:120\u2013125. https:\/\/doi.org\/10.1038\/sj.leu.2403187","journal-title":"Leukemia"},{"key":"3454_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"AK Schmaelter","year":"2020","unstructured":"Schmaelter AK, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M, Blaise D, Yakoub-Agha I et al (2020) Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J 10:26. https:\/\/doi.org\/10.1038\/s41408-020-0296-3","journal-title":"Blood Cancer J"},{"key":"3454_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"3454_CR40","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M et al (2018) Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59:2238\u20132241. https:\/\/doi.org\/10.1080\/10428194.2017.1422864","journal-title":"Leuk Lymphoma"},{"key":"3454_CR41","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC et al (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170:1120-1133.e1117. https:\/\/doi.org\/10.1016\/j.cell.2017.07.024","journal-title":"Cell"},{"key":"3454_CR42","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S et al (2018) A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24:994\u20131004. https:\/\/doi.org\/10.1038\/s41591-018-0057-z","journal-title":"Nat Med"},{"key":"3454_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM et al (2017) Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell 168:487-502.e415. https:\/\/doi.org\/10.1016\/j.cell.2016.12.022","journal-title":"Cell"},{"key":"3454_CR44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2326-6066.Cir-19-0574","volume":"8","author":"H Kagamu","year":"2020","unstructured":"Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M et al (2020) CD4(+) T-cell immunity in the peripheral blood correlates with response to Anti-PD-1 therapy. Cancer Immunol Res 8:334\u2013344. https:\/\/doi.org\/10.1158\/2326-6066.Cir-19-0574","journal-title":"Cancer Immunol Res"},{"key":"3454_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 18:87. https:\/\/doi.org\/10.1186\/s12916-020-01549-2","journal-title":"BMC Med"},{"key":"3454_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25:94\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"3454_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA et al (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood 129:1380\u20131388. https:\/\/doi.org\/10.1182\/blood-2016-09-738385","journal-title":"Blood"},{"key":"3454_CR48","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","volume":"35","author":"RW Merryman","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A et al (2021) Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 35:2672\u20132683. https:\/\/doi.org\/10.1038\/s41375-021-01193-6","journal-title":"Leukemia"},{"key":"3454_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","volume":"132","author":"C Herbaux","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F et al (2018) Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 132:9\u201316. https:\/\/doi.org\/10.1182\/blood-2018-02-811174","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03454-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:22:32Z","timestamp":1689996152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03454-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3454"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03454-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no financial or other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee of Chinese PLA General Hospital and investigators abided by Good Clinical Practice, as described in the International Council for Harmonization guideline E6 and in accordance with the general ethical principles as outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Signed informed consent was obtained from all patients or respective guardians prior to treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All analyses were performed using de-identified data and, as such, no patient personal information is presented in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}